CN105833278A - 用于治疗口腔干燥和口腔疾病的组合物 - Google Patents
用于治疗口腔干燥和口腔疾病的组合物 Download PDFInfo
- Publication number
- CN105833278A CN105833278A CN201610258020.8A CN201610258020A CN105833278A CN 105833278 A CN105833278 A CN 105833278A CN 201610258020 A CN201610258020 A CN 201610258020A CN 105833278 A CN105833278 A CN 105833278A
- Authority
- CN
- China
- Prior art keywords
- compositions
- xerostomia
- active component
- composition
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010013781 dry mouth Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 208000005946 Xerostomia Diseases 0.000 title claims abstract description 47
- 208000025157 Oral disease Diseases 0.000 title claims abstract description 18
- 208000030194 mouth disease Diseases 0.000 title claims abstract description 18
- 239000002562 thickening agent Substances 0.000 claims abstract description 24
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 230000002335 preservative effect Effects 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000000080 wetting agent Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 239000003002 pH adjusting agent Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
- 239000001509 sodium citrate Substances 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 235000019640 taste Nutrition 0.000 claims description 8
- 235000010418 carrageenan Nutrition 0.000 claims description 7
- 239000000679 carrageenan Substances 0.000 claims description 7
- 229920001525 carrageenan Polymers 0.000 claims description 7
- 229940113118 carrageenan Drugs 0.000 claims description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 3
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 3
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 229960005274 benzocaine Drugs 0.000 claims description 3
- 229960003260 chlorhexidine Drugs 0.000 claims description 3
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 3
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 claims description 3
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960005053 tinidazole Drugs 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- -1 Alumen Chemical compound 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 241000241413 Propolis Species 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 229940125716 antipyretic agent Drugs 0.000 claims description 2
- 229960004515 diclofenac potassium Drugs 0.000 claims description 2
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims description 2
- 229960001193 diclofenac sodium Drugs 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960000965 nimesulide Drugs 0.000 claims 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 15
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 14
- 208000007565 gingivitis Diseases 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 12
- 201000003465 angular cheilitis Diseases 0.000 abstract description 9
- 208000007287 cheilitis Diseases 0.000 abstract description 9
- 208000002925 dental caries Diseases 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 239000003906 humectant Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 16
- 210000000214 mouth Anatomy 0.000 description 14
- 239000002131 composite material Substances 0.000 description 8
- 201000001245 periodontitis Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 241000220223 Fragaria Species 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102100035769 Apoptotic chromatin condensation inducer in the nucleus Human genes 0.000 description 1
- 101710139767 Apoptotic chromatin condensation inducer in the nucleus Proteins 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
成分 | 功能 | 实施例1 | 实施例2 | 实施例3 |
二聚甘油 | 保湿剂 | — | 60g | — |
山梨醇 | 保湿剂 | 60g | — | — |
丙二醇 | 保湿剂 | — | — | 60g |
水 | 溶剂 | 37g | 36.1g | 36.5g |
羧甲基纤维素钠 | 增稠剂 | — | 3g | 2g |
明胶 | 增稠剂 | 2g | — | 1g |
卡拉胶 | 增稠剂 | 0.7g | 0.5g | — |
柠檬酸钾 | PH调节剂 | 0.2g | — | — |
柠檬酸钠 | PH调节剂 | — | 0.3g | 0.3g |
柠檬香精 | 矫味剂 | — | 0.05g | — |
草莓香精 | 矫味剂 | 0.05g | — | 0.1g |
对羟基苯甲酸乙酯 | 防腐剂 | — | 0.05g | — |
山梨酸钾 | 防腐剂 | 0.05g | — | — |
醋酸钠 | 防腐剂 | — | — | 0.1g |
总重 | 100g | 100g | 100g |
成分 | 功能 | 实施例4 |
丙二醇 | 保湿剂 | 60g |
水 | 溶剂 | 35g |
苯佐卡因 | 活性成分 | 2g |
羧甲基纤维素钠 | 增稠剂 | 2g |
卡拉胶 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
蜜桃香精 | 矫味剂 | 0.05g |
对羟基苯甲酸乙酯 | 防腐剂 | 0.05g |
总重 | 100g |
成分 | 功能 | 实施例5 |
二聚甘油 | 保湿剂 | 60g |
水 | 溶剂 | 35.2g |
氯己定 | 活性成分 | 1.5g |
醋酸*** | 活性成分 | 0.05g |
维生素B2 | 活性成分 | 0.15g |
羧甲基纤维素钠 | 增稠剂 | 2g |
卡拉胶 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
草莓香精 | 矫味剂 | 0.05g |
对羟基苯甲酸乙酯 | 防腐剂 | 0.05g |
总重 | 100g |
成分 | 功能 | 实施例6 |
二聚甘油 | 保湿剂 | 60g |
水 | 溶剂 | 32g |
青黛 | 活性成分 | 3g |
白矾 | 活性成分 | 1g |
冰片 | 活性成分 | 1g |
卡波姆 | 增稠剂 | 2g |
海藻酸钠 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
柠檬香精 | 矫味剂 | 0.05g |
山梨酸钾 | 防腐剂 | 0.05g |
总重 | 100g |
成分 | 功能 | 实施例7 |
二聚甘油 | 保湿剂 | 60g |
水 | 溶剂 | 35g |
替硝唑 | 活性成分 | 1.95g |
薄荷脑 | 活性成分 | 0.05g |
羧甲基纤维素钠 | 增稠剂 | 2g |
卡拉胶 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
甜菊素 | 矫味剂 | 0.05g |
对羟基苯甲酸乙酯 | 防腐剂 | 0.05g |
总重 | 100g |
成分 | 功能 | 实施例8 |
二聚甘油 | 保湿剂 | 60g |
水 | 溶剂 | 36g |
琥乙红霉素 | 活性成分 | 1g |
羧甲基纤维素钠 | 增稠剂 | 2g |
卡拉胶 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
草莓香精 | 矫味剂 | 0.05g |
对羟基苯甲酸乙酯 | 防腐剂 | 0.05g |
总重 | 100g |
成分 | 功能 | 实施例9 |
二聚甘油 | 保湿剂 | 60g |
水 | 溶剂 | 32g |
布洛芬 | 活性成分 | 5g |
羧甲基纤维素钠 | 增稠剂 | 2g |
卡波姆 | 增稠剂 | 0.7g |
柠檬酸钠 | pH调节剂 | 0.2g |
柠檬香精 | 矫味剂 | 0.05g |
对羟基苯甲酸乙酯 | 防腐剂 | 0.05g |
总重 | 100g |
实施例1 | 实施例2 | 实施例3 | |
凝胶剂消失时间(小时) | 5.8 | 6.5 | 6.3 |
实施例1 | 实施例2 | 实施例3 | |
凝胶剂消失时间(小时) | 5.9 | 6.8 | 6.2 |
实施例1 | 实施例2 | 实施例3 | |
凝胶剂消失时间(小时) | 6 | 7 | 6.2 |
样品 | 水分解吸度 |
实施例1 | 7.0% |
实施例2 | 6.9% |
实施例3 | 7.1% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610258020.8A CN105833278B (zh) | 2016-04-25 | 2016-04-25 | 用于治疗口腔干燥和口腔疾病的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610258020.8A CN105833278B (zh) | 2016-04-25 | 2016-04-25 | 用于治疗口腔干燥和口腔疾病的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105833278A true CN105833278A (zh) | 2016-08-10 |
CN105833278B CN105833278B (zh) | 2018-05-08 |
Family
ID=56588884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610258020.8A Active CN105833278B (zh) | 2016-04-25 | 2016-04-25 | 用于治疗口腔干燥和口腔疾病的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105833278B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107007503A (zh) * | 2017-04-26 | 2017-08-04 | 烟台新时代健康产业日化有限公司 | 一种抑菌组合物及其制备方法和应用 |
CN110693834A (zh) * | 2019-10-24 | 2020-01-17 | 大连怡爽口腔医疗科技有限公司 | 一种口腔润湿喷剂 |
CN112107543A (zh) * | 2019-06-19 | 2020-12-22 | 陕西佰傲再生医学有限公司 | 咽喉喷雾剂及其制备方法 |
CN115192598A (zh) * | 2022-09-13 | 2022-10-18 | 山东百多安医疗器械股份有限公司 | 一种用于缓解口角炎的敷贴 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396370A (zh) * | 2007-09-27 | 2009-04-01 | 北京天川军威医药技术开发有限公司 | 治疗口腔、咽喉疾病的药物组合物及其制备方法 |
CN102198126A (zh) * | 2011-05-04 | 2011-09-28 | 刘布鸣 | 治疗口腔及牙齿疾病的涂抹剂及其涂抹器 |
CN104225246A (zh) * | 2014-09-12 | 2014-12-24 | 皖南医学院 | 一种口腔溃疡膜剂及其制备方法 |
CN104955447A (zh) * | 2012-12-18 | 2015-09-30 | 日星瑞士股份公司 | 用于减轻口干燥症状和用于治疗口溃疡的局部口腔组合物 |
CN105307645A (zh) * | 2013-06-03 | 2016-02-03 | 麦克内尔股份公司 | 用于在口腔中释放至少一种活性药物成分的固体药物剂型 |
CA2970146A1 (en) * | 2014-12-10 | 2016-06-16 | Elevate Oral Care, Llc | Composition of clathrate and xylitol for the relief of dry mouth |
-
2016
- 2016-04-25 CN CN201610258020.8A patent/CN105833278B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396370A (zh) * | 2007-09-27 | 2009-04-01 | 北京天川军威医药技术开发有限公司 | 治疗口腔、咽喉疾病的药物组合物及其制备方法 |
CN102198126A (zh) * | 2011-05-04 | 2011-09-28 | 刘布鸣 | 治疗口腔及牙齿疾病的涂抹剂及其涂抹器 |
CN104955447A (zh) * | 2012-12-18 | 2015-09-30 | 日星瑞士股份公司 | 用于减轻口干燥症状和用于治疗口溃疡的局部口腔组合物 |
CN105307645A (zh) * | 2013-06-03 | 2016-02-03 | 麦克内尔股份公司 | 用于在口腔中释放至少一种活性药物成分的固体药物剂型 |
CN104225246A (zh) * | 2014-09-12 | 2014-12-24 | 皖南医学院 | 一种口腔溃疡膜剂及其制备方法 |
CA2970146A1 (en) * | 2014-12-10 | 2016-06-16 | Elevate Oral Care, Llc | Composition of clathrate and xylitol for the relief of dry mouth |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107007503A (zh) * | 2017-04-26 | 2017-08-04 | 烟台新时代健康产业日化有限公司 | 一种抑菌组合物及其制备方法和应用 |
CN112107543A (zh) * | 2019-06-19 | 2020-12-22 | 陕西佰傲再生医学有限公司 | 咽喉喷雾剂及其制备方法 |
CN110693834A (zh) * | 2019-10-24 | 2020-01-17 | 大连怡爽口腔医疗科技有限公司 | 一种口腔润湿喷剂 |
CN115192598A (zh) * | 2022-09-13 | 2022-10-18 | 山东百多安医疗器械股份有限公司 | 一种用于缓解口角炎的敷贴 |
Also Published As
Publication number | Publication date |
---|---|
CN105833278B (zh) | 2018-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2520745C2 (ru) | Лекарственная композиция для лечения бронхита и способ ее получения | |
CN102079794B (zh) | 用于医药装置和药物制剂中的含有木葡聚糖的粘膜粘附性制剂 | |
JP4465155B2 (ja) | 粘膜損傷の治療用薬草組成物 | |
Moghadamnia et al. | The efficacy of the bioadhesive patches containing licorice extract in the management of recurrent aphthous stomatitis | |
CN106924378B (zh) | 一种防治和/或治疗慢性唇炎的中草药唇膏 | |
CN105833278A (zh) | 用于治疗口腔干燥和口腔疾病的组合物 | |
Neena et al. | An ancient herb aloevera in dentistry: A review | |
JP2009530350A (ja) | ***単純ヘルペス感染症の治療および/または予防のための局所使用用スプレー組成物 | |
EP3661490B1 (en) | Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis | |
CN106138190B (zh) | 一种外用凝胶制剂、制备方法及其用途 | |
JP2000512270A (ja) | 単純ヘルペスの処置のための組成物および方法 | |
US11806376B2 (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
JP3103373B2 (ja) | ククイナット外皮由来の抗ウイルス剤 | |
CN108403764B (zh) | 一种用于治疗颜面再发性皮炎的外用制剂及制备方法 | |
WO2022047729A1 (zh) | 一种止泻栓剂中药组合物及其制备方法和应用 | |
CN113842440B (zh) | 一种用于治疗银屑病的中药组合物 | |
Chandrashekar | Comparative study on the efficacy of Topical Curcumin as a gel and as Buccal Mucoadhesive Patch in the management of oral Submucous Fibrosis-A clinicobiochemical evaluation | |
JP2023145935A (ja) | 沢瀉湯エキス製剤 | |
CN116747263A (zh) | 一种治疗复发性口腔溃疡的中药组合物、中药制剂及其制备方法 | |
CN100450538C (zh) | 一种治疗中风后遗症的中药制剂 | |
CN104587034A (zh) | 一种药物组合物在用于制备治疗口腔溃疡的新用途 | |
CN115414410A (zh) | 一种改善口腔溃疡的芡实壳浸膏及其制备方法和应用 | |
CN114832059A (zh) | 治疗寻常型银屑病的复方蜈蚣组合物及其制备方法、用途 | |
CN111084741A (zh) | 赤芍提取物在制备口腔护理用品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 102609 Beijing City, Daxing District biological medicine industry base AEON Road No. 26 Hospital of Zhongguancun Medical Park Building No. 16 Applicant after: BEIJING CHIRAL-TECH PHARMACEUTICAL CO., LTD. Address before: 101111 Beijing City, Daxing District branch of Beijing economic and Technological Development Zone, fourteen Street No. 99 Building No. 7 Room 501 Applicant before: BEIJING CHIRAL-TECH PHARMACEUTICAL CO., LTD. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Suyun Inventor after: Feng Puchun Inventor before: Liu Suyun Inventor before: Feng Puchun Inventor before: Di Zhong Inventor before: Huang Qiaoping |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171009 Address after: 102609 Beijing City, Daxing District biological medicine industry base AEON Road No. 26 Hospital of Zhongguancun Medical Park Building No. 16 Applicant after: Beijing jia'an Medical Technology Co Ltd Address before: 102609 Beijing City, Daxing District biological medicine industry base AEON Road No. 26 Hospital of Zhongguancun Medical Park Building No. 16 Applicant before: BEIJING CHIRAL-TECH PHARMACEUTICAL CO., LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180626 Address after: 102609 301, room 16, building 16, Zhongguancun medical instrument garden, No. 26, Yong Wang Xi Road, Daxing District bio pharmaceutical industrial base, Beijing. Patentee after: Beijing Rev Medical Instrument Co., Ltd. Address before: 102609 Beijing Daxing District biomedical industry base No. 26, Zhongguancun medical instrument garden 16, wing Wan West Road. Patentee before: Beijing jia'an Medical Technology Co Ltd |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 102609 301, room 16, building 16, Zhongguancun medical instrument garden, No. 26, Yong Wang Xi Road, Daxing District bio pharmaceutical industrial base, Beijing. Patentee after: Beijing Qihui Biomedical Co., Ltd. Address before: 102609 301, room 16, building 16, Zhongguancun medical instrument garden, No. 26, Yong Wang Xi Road, Daxing District bio pharmaceutical industrial base, Beijing. Patentee before: Beijing Rev Medical Instrument Co., Ltd. |